NAPEPLD

Across TCGA pan-cancer cohorts, NAPEPLD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAPEPLD data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAPEPLD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NAPEPLD expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NAPEPLD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.612	0.243	<.001	64	view →
CCRCC	OS	Tertile	All	0.911	0.680	.004	21	view →
LUAD	OS	Tertile	III,IV	0.747	0.236	.042	6	view →
LSCC	OS	Tertile	All	0.538	0.884	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAPEPLD–PDAC (DFS)

Open the PDAC breakdown →